Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Bio-Rad Laboratories Q4 2023 Adj EPS $3.10 Beats $2.82 Estimate, Sales $681.20M Miss $685.09M Estimate

Author: Benzinga Newsdesk | February 15, 2024 05:16pm
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $3.10 per share which beat the analyst consensus estimate of $2.82 by 9.93 percent. The company reported quarterly sales of $681.20 million which missed the analyst consensus estimate of $685.09 million by 0.57 percent. This is a 6.72 percent decrease over sales of $730.29 million the same period last year.

Posted In: BIO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist